Drug Database
DT

DTP-HBV-Hib vaccine (Comvac5)

✓ Approved

Bharat Biotech Ltd. · Vaccine · Vaccine

What is DTP-HBV-Hib vaccine?

DTP-HBV-Hib vaccine is a vaccine developed by Bharat Biotech Ltd.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesComvac5
CompanyBharat Biotech Ltd.
Drug ClassVaccine
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bharat Biotech Ltd.

Therapeutic Indications

DTP-HBV-Hib vaccine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedInternational journal of molecular sciences2026-10-16

Immune Profiles Elicited by Different HBV Vaccine Modalities and Their Associations with Serological and Intrahepatic Viral Outcomes.

Xiao Huiying H, He Jinhang J, Zhu Lili L, Wang Songmei S et al.

Therapeutic vaccination for chronic hepatitis B aims to restore HBV-specific T-cell immunity and contribute to a functional cure. We systematically compared the immune profiles and antiviral efficacy of four vaccine modalities: recombinant HBsAg (rHBsAg), antigen-antibody immune complex (IC), a DNA vaccine encoding HBsAg (DNA-HBsAg), and an HBsAg-Fc fusion DNA vaccine (DNA-HBsAg-Fc). In naïve mice, the rHBsAg vaccine predominantly induced anti-HBs IgG responses, whereas the IC vaccine elicited strong anti-HBs IgG and detectable CD4+ T-cell responses. In contrast, DNA vaccines preferentially induced HBsAg-specific CD8+ T-cell immunity, which was further enhanced by fusion to the Fc fragment of human IgG1. In the pre-immunization/AAV-HBV model, high anti-HBs titers in rHBsAg and IC groups were associated with rapid clearance of circulating HBsAg but not with comparable reductions in HBcAg+ hepatocytes, whereas stronger HBsAg-specific CD8+ T-cell responses in the DNA vaccine groups were associated with greater reductions in HBcAg+ hepatocytes. However, in the therapeutic AAV-HBV model, all vaccine monotherapies showed limited and non-sustained antiviral efficacy, with only transient reductions in serum HBsAg and limited reductions in HBcAg+ hepatocytes. These findings highlight the distinct immune profiles of different vaccine platforms and an association between stronger HBsAg-specific CD8+ T-cell responses and reduced intrahepatic HBcAg expression, while underscoring the limited efficacy of vaccine monotherapy in the AAV-HBV model.

PMID 42883747
Read full article →
PubMedFoods (Basel, Switzerland)2026-10-16

Structural Features of a Dancong Tea Polysaccharide and Its Amelioration of Glucolipid Metabolic Disorders Associated with Gut Microbiota Modulation.

Lin Run R, Wang Zhe Z, Chen Zhiyang Z, Cen Ruisen R et al.

A novel acidic polysaccharide, Dancong tea polysaccharide (DTP), was obtained from Dancong tea, and its structural characteristics and regulatory effects on glucolipid metabolism were investigated. With a molecular weight of 52 kDa, DTP is a pectic polysaccharide consisting mainly of a linear α-1,4-linked homogalacturonan backbone (72.7% galacturonic acid) with a methyl-esterification degree of 34.12%. In C57BL/6J mice fed a high-fat diet (HFD), administration of DTP effectively alleviated obesity, insulin resistance, dyslipidemia, and hepatic steatosis, which was accompanied by attenuated oxidative stress and inflammation. 16S rRNA gene sequencing demonstrated that DTP ameliorated gut dysbiosis through targeted regulation of specific taxa rather than a broad reversal at the phylum level. The medium dose of DTP reduced the abundance of obesity-associated genera (Allobaculum, Dubosiella), while high-dose DTP enriched beneficial Bifidobacterium species. Correlation analysis indicated that these microbial shifts were closely associated with the restoration of glucose and lipid homeostasis. Overall, our findings support the potential of DTP as a functional prebiotic ingredient for the management of metabolic diseases.

PMID 42883471
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-10-16

Association Between HIV-1 RNA Detection Status and HBV DNA Detection: A Patient-Level Retrospective Longitudinal Molecular Study from Istanbul, Türkiye.

Yaman Murat M, Alay Kara Kubra K

Background/Objectives: HIV and hepatitis B virus (HBV) share major transmission routes and may coexist in the same individual, making coordinated molecular assessment clinically important. Methods: This retrospective longitudinal laboratory-based study evaluated the patient-level association between HIV-1 RNA detection and HBV DNA detection using routine molecular testing data from a tertiary-care hospital in Istanbul, Türkiye. HIV-1 RNA and HBV DNA results obtained between 1 January 2022 and 1 August 2026 were linked at the patient level. A total of 5303 unique patients had HIV-1 RNA testing and 30,981 unique patient records had HBV DNA testing; these were separate source populations, and 529 individuals with results available for both molecular assays constituted the primary analytical cohort. Results: Among the 529 patients, HIV-1 RNA was detected at least once in 246 (46.5%), while HBV DNA was detected at least once in 147 (27.8%). HBV DNA detection occurred in 83/246 (33.7%) patients with at least one detectable HIV-1 RNA result and in 64/283 (22.6%) patients with no detectable HIV-1 RNA in any available measurement (OR, 1.74; 95% CI, 1.19-2.56; p = 0.005). However, the association was attenuated after adjustment for age and sex and was no longer statistically significant (adjusted OR, 1.28; 95% CI, 0.84-1.94; p = 0.255). HIV-1 RNA magnitude and HIV-1 RNA categories were not significantly associated with HBV DNA detection, and no significant correlation was observed between same-day HIV-1 RNA and HBV DNA levels (Spearman's ρ = 0.161; p = 0.387) or between the nearest quantitative measurements obtained within ±30 days (ρ = 0.171; p = 0.245). Because treatment exposure and adherence information were unavailable, the observed molecular patterns could not be interpreted as direct measures of treatment response or treatment failure. Conclusions: These findings indicate that HIV-1 RNA detection status or magnitude should not be used as a surrogate for HBV DNA detection and support independent, clinically indicated HBV assessment in people living with HIV.

PMID 42882369
Read full article →
PubMedMilitary medicine2026-10-16

The Case for Dedicated Vaccine Communication Training: A Survey of Military Pediatricians.

Auvil Daley D, Jones Katherine K, Ratusnik Rebecca R, Adams Daniel J DJ

Vaccine uncertainty is rising among families in the United States, even among military families. The ACGME mandates that pediatric residents be trained in effective communication strategies for patients and families hesitant about recommended vaccinations, yet few validated curriculum tools exist. We aimed to understand the current landscape of vaccine uncertainty experienced by military general pediatricians and see what communication strategies were routinely being implemented in clinical practice. In March 2025, 45 graduates of a mid-sized military pediatrics residency program from the years 2016-2024 who were currently practicing general pediatricians were invited to participate in a survey on vaccine communication in clinical practice. The survey was a mix of quantitative questions asking for experienced trends in vaccine uncertainty as well as open-ended questions about communication strategies being implemented. Three clinical researchers performed a manual thematic analysis of free-text answers to understand and quantify common themes. Thirty-seven general pediatricians (82%) responded, and 95% of those surveyed rated a curriculum during medical training on vaccine communication as "very" or "extremely important." Only 19% of physicians were able to recall formal training in addressing vaccine hesitancy during medical school, and only 62% during residency. The 3 most commonly declined vaccines were COVID-19, influenza, and HPV. Pediatricians reported using communication strategies focused on knowledge-sharing (65%), partnership with families (62%), and normalizing vaccines (40%). Common barriers to vaccine acceptance were mistrust and disinterest, most commonly with unwillingness to engage in a conversation. Most practicing military pediatricians who graduated from our residency program report a rise in vaccine uncertainty in their practice and agree that a residency curriculum on vaccine communication is highly important. Such curricula should encourage evidence-based communication styles using vaccine normalization while de-emphasizing the urge to combat misinformation using knowledge-sharing and should specifically address the most commonly declined immunizations.

PMID 42885154
Read full article →
PubMedNature communications2026-10-16

Klebsiella-dominant gut communities are associated with impeded oral rotavirus vaccine response in infants.

Seymour Cale O CO, Ecklu-Mensah Gertrude G, Lee Yesun Y, Nicols Alexander R AR et al.

Rotavirus gastroenteritis is the leading cause of infant diarrheal death worldwide. Oral rotavirus vaccine (RVV) prevents illness and death, but efficacy differs between high- and low-income countries and the etiologies are unclear. Here, we describe the relationship between colonization of the infant gut by commensal bacteria, inflammation, and vaccine response across a cohort of infants from Panama, Peru, and the U.S. Vaccine immunogenicity was related to community composition in the first month of life and inverse to increased relative abundance of Klebsiella. Clustering communities into gut types revealed that microbiome configurations with elevated Klebsiella or Escherichia in the first month of life were negatively associated with both seroconversion and rotavirus shedding after vaccination, suggesting potential inhibition of vaccine function or host response. Infants without RVV strain shedding displayed elevated fecal calprotectin in the first month. These results implicate microbiome-augmented infant gut inflammation as a potential impediment to RVV response.

PMID 42881193
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Closing the Gap: Advances and Barriers on Candida Vaccines Development in the Last Decade.

Krier Julie J, Allkja Jontana J, Viana da Costa Alexandra Mónica Bastos AMB, Silva Francisco A M FAM et al.

Invasive Candidiasis (IC) remains a critical threat to global health. Primarily caused by Candida albicans, it is increasingly driven by emerging Non-Candida albicans Candida Species (NCACs). IC typically arises from the overgrowth of commensal Candida species in immunocompromised hosts. IC accounts for an estimated 250,000-700,000 cases annually worldwide, with mortality rates between 40 and 55%, and contributes to more than 1.5 million annual deaths. Despite progress in healthcare systems, intensive care, and microbiological techniques, mortality rates remain largely unchanged. Triazole resistance is already widespread, and echinocandin resistance, while still low, is steadily climbing. The emergence of multidrug-resistant Candida auris, the growing immunocompromised population, and the absence of any antifungal vaccine collectively define this scenario as a therapeutic impasse. Given these challenges, there is an urgent need to synthesize current vaccine research to identify robust candidates and address lingering translational bottlenecks. This structured narrative review evaluates the advances and barriers in Candida spp. vaccine development over the past decade (2015-2025), structured around epidemiology and resistance; immunological framework underpinning vaccine design; antigenic targets and delivery platforms; and preclinical and clinical evidence. Key milestones included the Phase II clinical validation of NDV-3A, the first successful large-scale human trial of a fungal vaccine; the standardization of the A/J mouse model for C. auris; the emergence of multi-epitope computational platforms with >94% HLA population coverage; and cross-kingdom protection paradigms. Major obstacles included commensal-to-pathogen duality of Candida, immunocompromised host paradox, antigenic plasticity, and chronic underinvestment. Converging next-generation vaccine strategies are beginning to bridge the gap between bench discovery and clinical implementation.

PMID 42883739
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about DTP-HBV-Hib vaccine